Analytical Data
-
Gene name
APOA2
- Application
-
Alternative Names
Apo-A2; Apolipoprotein A-II; ProapoA-II; Truncated apolipoprotein A-II
-
Species
Human
-
Source
HEK293
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P02652
-
Expression Region
Gln24~Gln100
-
Molecular Weight
12&13.5&14kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Apolipoprotein A2 (APOA2) is a significant protein component of high-density lipoproteins (HDL) in the human body, playing a crucial role in lipid metabolism, cholesterol transport, and cardiovascular health. Its relevance has been underscored by studies linking variations in the APOA2 gene to obesity, metabolic disorders, and the modulation of HDL cholesterol levels. Despite its importance, the detailed mechanism of action and the pathway through which APOA2 influences lipid metabolism remain poorly understood. To elucidate these mechanisms, research has focused on the production of recombinant APOA2 proteins, enabling detailed investigation of their structural and functional properties. The utilization of recombinant DNA technology permits the generation of large quantities of pure APOA2, facilitating biochemical studies and functional assays. These studies aim to explore how APOA2 interacts with lipids and other proteins in the extracellular environment, as well as its role in influencing the composition and functionality of HDL particles. Additionally, understanding the structural characteristics of recombinant APOA2 can provide insights into its stability, ligand binding, and potential therapeutic applications for conditions related to dyslipidemia and atherosclerosis. Overall, the research on recombinant APOA2 not only enhances our comprehension of lipid metabolism but also opens new avenues for the development of novel therapeutic strategies targeting cardiovascular diseases.
